News

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Capricor falls after report on AdCom meeting cancellation (update)
Capricor Therapeutics (NASDAQ:CAPR) plunged 32% following a trading halt on Friday after Stat News reported that the new head ...
Investing.com India5h
Capricor Therapeutics stock plunges after key FDA officials placed on leave
Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 20.4% following news that two top FDA officials overseeing cell and gene therapies have been placed on administrative leave.
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's ...